Dr Peter Clark forecasts the booming M&A cycle to come to an end during the second quarter of 2017. With megadeals hitting the headlines on a regular basis – the latest Pfizer Inc.’s announcement to merge with Allergen PLC in a $155 billion deal – Clark says while none of them have sounded major alarm bells on their own, the sheer volume is worthy of note. “Mergers, IPOs and stock markets tend to collapse together in concert,” says Clark.